Artículos con órdenes de acceso público - Cervantes AMás información
No disponibles: 5
Personalised treatment in gastric cancer: myth or reality?
N Tarazona, V Gambardella, M Huerta, S Rosello, A Cervantes
Current oncology reports 18 (7), 41, 2016
Randomized study of sequential cisplatin-topotecan/carboplatin-paclitaxel versus carboplatin-paclitaxel: effects on quality of life
L Brotto, M Brundage, P Hoskins, I Vergote, A Cervantes, HA Casado, ...
Supportive Care in Cancer 24 (3), 1241-1249, 2016
P37 Phase 1 evaluation of bintrafusp alfa (M7824), a bifunctional fusion protein targeting TGF-β and PD-L1, in cervical cancer
S Allan, F Braiteh, EC Aller, A Cervantes, W Edenfield, T Li, M Rasschaert, ...
International Journal of Gynecologic Cancer 29 (Suppl 4), 2019
Improving tumour budding evaluation in colon cancer by extending the assessment area in colectomy specimens
C Martinez‐Ciarpaglini, C Fernandez‐Sellers, N Tarazona, S Roselló, ...
Histopathology 75 (4), 517-525, 2019
Disponibles: 58
A phase 3 trial of bevacizumab in ovarian cancer
TJ Perren, AM Swart, J Pfisterer, JA Ledermann, E Pujade-Lauraine, ...
New England Journal of Medicine 365 (26), 2484-2496, 2011
Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
R Glynne-Jones, L Wyrwicz, E Tiret, G Brown, C Rödel, A Cervantes, ...
Annals of Oncology 28, iv22-iv40, 2017
Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial
AM Oza, AD Cook, J Pfisterer, A Embleton, JA Ledermann, ...
The Lancet Oncology 16 (8), 928-936, 2015
First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase …
E Díaz-Rubio, A Gómez-España, B Massutí, J Sastre, A Abad, ...
The oncologist 17 (1), 15, 2012
Ebola virus disease cluster in the United States—Dallas county, Texas, 2014
MS Chevalier, W Chung, J Smith, LM Weil, SM Hughes, SN Joyner, E Hall, ...
MMWR. Morbidity and mortality weekly report 63 (46), 1087, 2014
Evaluation and clinical analyses of downstream targets of the Akt inhibitor GDC-0068
Y Yan, V Serra, L Prudkin, M Scaltriti, S Murli, O Rodríguez, M Guzman, ...
Clinical Cancer Research 19 (24), 6976-6986, 2013
TP53 mutational status and cetuximab benefit in rectal cancer: 5-year results of the EXPERT-C trial
F Sclafani, D Gonzalez, D Cunningham, S Hulkki Wilson, C Peckitt, ...
JNCI: Journal of the National Cancer Institute 106 (7), 2014
Definition of the rectum: an international, expert-based Delphi consensus
N D'Souza, MPMN tot Babberich, A d’Hoore, E Tiret, E Xynos, ...
Annals of surgery 270 (6), 955-959, 2019
Deregulation of ARID1A, CDH1, cMET and PIK3CA and target-related microRNA expression in gastric cancer
M Ibarrola-Villava, MJ Llorca-Cardeñosa, N Tarazona, C Mongort, ...
Oncotarget 6 (29), 26935, 2015
Efficacy and determinants of response to HER kinase inhibition in HER2-mutant metastatic breast cancer
LM Smyth, SA Piha-Paul, HH Won, AM Schram, C Saura, S Loi, J Lu, ...
Cancer discovery 10 (2), 198-213, 2020
Intratumoral adaptive immunosuppression and type 17 immunity in mismatch repair proficient colorectal tumors
NJ Llosa, B Luber, AJ Tam, KN Smith, N Siegel, AH Awan, H Fan, T Oke, ...
Clinical Cancer Research 25 (17), 5250-5259, 2019
NRF2 through RPS6 activation is related to anti-HER2 drug resistance in HER2-amplified gastric cancer
V Gambardella, F Gimeno-Valiente, N Tarazona, CM Ciarpaglini, D Roda, ...
Clinical Cancer Research 25 (5), 1639-1649, 2019
Exploratory outcome analyses according to stage and/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian …
A Gonzalez Martin, A Oza, AC Embleton, J Pfisterer, J Ledermann, ...
Gynecologic Oncology 152 (1), 2019
Analytical validation of multiplex biomarker assay to stratify colorectal cancer into molecular subtypes
C Ragulan, K Eason, E Fontana, G Nyamundanda, N Tarazona, Y Patil, ...
Scientific reports 9 (1), 1-12, 2019
FCGR polymorphisms and cetuximab efficacy in chemorefractory metastatic colorectal cancer: an international consortium study
R Geva, L Vecchione, KT Kalogeras, BV Jensen, HJ Lenz, T Yoshino, ...
Gut 64 (6), 921-928, 2015
La información de publicación y financiación se determina de forma automática mediante un programa informático